arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Aprea Therapeutics, Inc.

APRE
$0.77 ▼ -0.01 (-1.86%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
36 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Aprea Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $41.2M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -8.3% ↘
FCF / Share $-0.06 ↗
Trailing P/E —
Price / Book 0.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 24, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-3.29M
↑ +16.4% —
FCF / Share Free cash flow per share
$-0.06
↑ +67.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
8
Cash Quality →
67

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 10 years · 36 quarters